KOY.F Kobayashi Pharmaceutical Co. Ltd
- Market cap
- EUR 2.88B
- P/E
- 114.1x
- P/B
- 2.38x
- ROE
- 4.9%
- Dividend yield
- 1.51%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is KOY.F undervalued?
Graham numberThe Graham number of Kobayashi Pharmaceutical Co. Ltd cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Kobayashi Pharmaceutical Co. Ltd fundamental analysis
No fundamental analysis for Kobayashi Pharmaceutical Co. Ltd yet.
Kobayashi Pharmaceutical Co. Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Kobayashi Pharmaceutical Co. Ltd
Kobayashi Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sells OTC pharmaceuticals, guasi-drugs, deodorizing air fresheners, and sanitary products in Japan, the United States, Southeast Asia, and internationally. The company offers Ammeltz, an anti-inflammatory pain relief medicine; Dent, an effervescent denture cleaning agent; Ekitai Bluelet Okudake, a toilet bowl cleaner; Naicitol, a Chinese herbal medicine that promotes the breakdown and metabo…
Full company profileKobayashi Pharmaceutical Co. Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Kobayashi Pharmaceutical Co. Ltd annual financial statements (JPY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 153B | 157B | 167B | 168B | 151B | 155B | 166B | 173B | 166B | 166B | 151B |
| Gross Profit | 89.9B | 95.5B | 103B | 103B | 85.3B | 88.8B | 92.3B | 96.4B | 87.6B | 84.7B | 77.7B |
| Operating Income | 18.9B | 22.9B | 26.3B | 26.4B | 25.9B | 26.1B | 26.7B | 25.8B | 24.9B | 14.9B | 9.02B |
| EBITDA | - | 26.1B | 28.7B | 31.0B | 30.8B | 32.5B | 33.3B | 33.6B | 22.0B | 12.5B | 13.3B |
| Net Income | 15.3B | 15.9B | 18.0B | 19.1B | 19.2B | 19.7B | 20.0B | 20.3B | 10.1B | 3.66B | 10.3B |
| EPS | - | 201 | 228 | 245 | 246 | 254 | 263 | 274 | 135 | 49 | 139 |
| Balance Sheet | |||||||||||
| Total Assets | 201B | 219B | 231B | 233B | 238B | 253B | 256B | 267B | 265B | 275B | 250B |
| Total Liabilities | 57.9B | 65.0B | 64.7B | 60.7B | 55.8B | 57.0B | 57.9B | 62.7B | 51.9B | 64.3B | 40.4B |
| Shareholders' Equity | 143B | 154B | 166B | 173B | 183B | 196B | 198B | 205B | 213B | 211B | 210B |
| Cash & Short-term Investments | 58.2B | 65.0B | 74.5B | 75.6B | 78.3B | 95.0B | 96.2B | 71.5B | 50.9B | 62.3B | 50.0B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 21.5B | 22.4B | 20.0B | 20.1B | 24.0B | 22.4B | 31.9B | 18.4B | 11.2B | 25.6B | - |
| Capital Expenditure | 3.80B | 2.84B | 3.42B | 4.38B | 3.80B | 3.66B | 14.7B | 13.6B | 26.6B | 14.0B | 0.00 |
| Free Cash Flow | - | 19.1B | 16.3B | 15.3B | 19.8B | 18.2B | 15.7B | 4.79B | -15.4B | 11.6B | - |
| Ratios | |||||||||||
| ROE | 10.7% | 10.3% | 10.8% | 11.1% | 10.5% | 10.1% | 10.1% | 9.9% | 4.7% | 1.7% | 4.9% |
| ROA | 7.6% | 7.2% | 7.8% | 8.2% | 8.1% | 7.8% | 7.8% | 7.6% | 3.8% | 1.3% | 4.1% |
| Net Profit Margin | 10.0% | 10.1% | 10.8% | 11.4% | 12.8% | 12.7% | 12.0% | 11.7% | 6.1% | 2.2% | 6.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Kobayashi Pharmaceutical Co. Ltd dividends
- Dividend yield
- 1.51%
- Forward dividend
- 0.57 EUR
- Payout ratio
- 209.3%
- Ex-dividend date
- Dec 29, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | JPY 7.65B | 103 | 209.3% |
| 2024 | JPY 7.51B | 101 | 74.6% |
| 2023 | JPY 7.22B | 97 | 35.5% |
| 2022 | JPY 6.51B | 86 | 32.5% |
| 2021 | JPY 6.25B | 80 | 31.7% |
| 2020 | JPY 5.78B | 74 | 30.1% |
| 2019 | EUR 5.33B | 68 | 27.9% |
| 2018 | EUR 4.82B | 61 | 26.7% |
| 2017 | EUR 4.34B | 55 | 27.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Jun 28, 2016.
Who owns Kobayashi Pharmaceutical Co. Ltd
- Insiders 30.81%
- Institutions 26.08%
- Public & others 43.11%
- Shares outstanding 74.3M
- Free float 35.9M
Kobayashi Pharmaceutical Co. Ltd company profile
- Company name
- Kobayashi Pharmaceutical Co. Ltd
- Ticker
- KOY.F
- ISIN
- JP3301100008
- Exchange
- Frankfurt Exchange
- Sector
- Consumer Defensive
- Industry
- Personal Care Products
- Employees
- 3,731
- Fiscal year end
- December
- Address
- KDX Kobayashi Doshomachi Building, Osaka, Japan, 541-0045
- Phone
- 81 6 6231 1144
- Website
- kobayashi.co.jp
About Kobayashi Pharmaceutical Co. Ltd
Kobayashi Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sells OTC pharmaceuticals, guasi-drugs, deodorizing air fresheners, and sanitary products in Japan, the United States, Southeast Asia, and internationally. The company offers Ammeltz, an anti-inflammatory pain relief medicine; Dent, an effervescent denture cleaning agent; Ekitai Bluelet Okudake, a toilet bowl cleaner; Naicitol, a Chinese herbal medicine that promotes the breakdown and metabolism of fat; BreathCare, an oral breath freshener capsule; Netsusama sheet, a cooling gel sheet; and deodorizing air fresheners, lens cleaners, and oral hygiene products. It also manufactures and sells pharmaceuticals, fragrances, deodorants, cosmetics, health food, synthetic resin processed products, paper products, and hand warmers; and sells daily necessities. In addition, the company engages in transportation, real estate management, advertising planning and production, sales promotion and market research, promotional goods production and sales, and asset management activities, as well as in pharmacy, retail, and cleaning industries. Kobayashi Pharmaceutical Co., Ltd. was founded in 1886 and is headquartered in Osaka, Japan.
Kobayashi Pharmaceutical Co. Ltd management
10- Norikazu ToyodaPresident, CEO, Managing Executive Officer, GM of Research & Development and Director · born 1964
- Ms. Yumi NakagawaExecutive Officer & Chief of Finance
- Takayuki KimuraExecutive Officer, GM of General Affairs Dept & Human Resources Dept and Head of Public Relations
- Kenji KoboriExecutive Officer & Head of Sales Headquarters
- Atsushi OnoyamaManaging Exec Offc., Head of the Marketing Div & GM of Household Products Glob. Dept - Household Div
- Mr. Akihiro KobayashiDirector, Executive Officer & Head of Compensation Response Division · born 1971
- Mr. Fujito OhwakiManaging Executive Officer & GM of Healthcare Division
- Kei SatoExecutive Officer, Head of Compensation Division & Head of Corporate Strategy Division
- Mr. Keisuke KajitaHead of Food Section of Health Care Department
- Atsushi UenoharaCorporate Communications Department